ArticleJournal of family medicine and primary care2025
Impact of lifestyle modification practices and pharmacogenetics of
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension is a chronic disease whose prevalence is gradually increasing in society. It causes disease burden for a country, especially in low and middle-income countries. The present study aimed at analysing the impact of lifestyle modification practices and the role of pharmacogenetics of anti-hypertensive drugs in hypertensive patients susceptible to Materials and Methods: A hospital-based cross-sectional study was done on 447 hypertensive patients (grade 1) with age >20 years, both genders, with and without co-morbid diseases, taking anti-hypertensive drugs for more than one year, were recruited for the study. By convenience sampling method, 100 hypertensive patients taking amlodipine (5 mg/day) or telmisartan (20 mg/day) for more than one year were enlisted from the initially recruited study group, along with 100 healthy volunteers. Results: Patients who practiced various lifestyle modifications were seen to have good control ( Conclusion: The present study showed that lifestyle modification along with individualized drug therapy is vital in controlling blood pressure in grade 1 hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.